Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Official Title

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial


Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Trial Description

Primary Outcome:

  • Objective response rate defined as the number of patients with complete response or partial response
Secondary Outcome:
  • Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug
  • Progression-free survival by disease-appropriate objective criteria
Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumours that might be responsible for their malignant behaviour such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centres and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumours to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumour profiling and have 'druggable' changes identified in their cancers.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society